Develops treatments for genetically driven neuromuscular diseases, including muscular dystrophies and Pompe disease.
10-K for FY2025, filed Mar 2, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 2, 2026
10-Q for Q3 FY2026, filed Nov 5, 2026
−$193.6MView ↗
8-K, filed Jul 29, 2026
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target…View ↗
8-K, filed Jul 22, 2026
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering…View ↗
Pompe and enzyme medicines
The older report described programs for myotonic dystrophy, Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy, using oligonucleotide payloads; the latest report adds Pompe disease and an enzyme payload.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 2, 2026
Broader delivery target
The older report described FORCE as delivering treatments to muscle; the latest also describes delivery to the central nervous system.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 2, 2026Oligonucleotide therapeutics are a genetic medicine modality that, using nucleic acids, specifically aims to correct the function of…View ↗
We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular…View ↗
Competes with PTC Therapeutics, Catalyst Pharmaceuticals, ITF Therapeutics, Sarepta Therapeutics, Nippon Shinyaku, Wave Life Sciences, Entrada Therapeutics, BioMarin Pharmaceuticals, SQY Therapeutics, NS Pharma, Avidity, Solid Biosciences, REGENXBIO, Genethon, Insmed, Vertex, AMO Pharma, Harmony Biosciences, Pepgen, and Arrowhead Pharmaceuticals
10-K for FY2025, filed Mar 2, 2026Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is…View ↗
Loading...